New combo aims to outsmart resistant prostate cancer
NCT ID NCT02452008
Summary
This study is testing if adding an experimental drug called LY2157299 to the standard drug enzalutamide can help men with advanced prostate cancer that has stopped responding to hormone therapy. It will compare how long the cancer stays under control with the combination versus enzalutamide alone. The goal is to see if this new approach can overcome the cancer's resistance to treatment and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.